复星医药自研MEK抑制剂获批国内上市,这种罕见血液肿瘤有药可治了

第一财经
29 May

5月29日,复星医药(600196.SH、02196.HK)宣布,该公司自主研发的1类新药芦沃美替尼片正式获得国家药监局批准上市,成为国内首款可用于朗格汉斯细胞组织细胞增生症(LCH)成人患者治疗的药物。  朗格汉斯细胞组织细胞增生症(LCH)和埃尔德海姆-切斯特病(ECD),属于罕见血液系统肿瘤,80%以上LCH、ECD患者累及全身多系统,常常表现为:骨痛,丘疹或皮肤溃疡,心脏病如心衰、心梗、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10